While most cell therapies in development modify DNA, Cartesian Therapeutics is focused on using their RNA Armory technology to create cell therapies for various autoimmune, oncologic, and respiratory indications. The company recently announced data from their phase 1b/2a trial (NCT04146051) of Descartes-08, an mRNA-modified CAR T-cell therapy product, in myasthenia gravis (MG). Data showed improvements […]

The patent landscape allows you to protect your intellectual property — the unique discoveries and inventions you’ve made that nobody else has thought of. There are several kinds of patents. One is called a “prophetic patent,” filed when you don’t yet have data supporting a robust patent idea but can reasonably expect to have it […]

Treatment with Descartes-08, an investigational CAR T-cell therapy, markedly eased symptoms of myasthenia gravis (MG) in three patients participating in a Phase 1/2 clinical trial assessing the therapy’s safety and preliminary efficacy. “This is the first clinical trial of CAR T-cells for an autoimmune disease. Naturally, the first patients enrolled are some of our most severely affected […]